NR1H4 and metabolic dysfunction-associated steatohepatitis: Preclinical and clinical investigations reported tropifexor (LJN452) and nidufexor (LMB763) as potent FXR agonists; most potent being tropifexor while in individuals with NASH and nephropathy, nidufexor has moved to phase II clinical trials [41–43].